Credit Suisse Ag Krystal Biotech, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 321,946 shares of KRYS stock, worth $57.2 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

321,946

Previous 474,484 32.15%

Holding current value

$57.2 Million

Previous $58.9 Million 2.69%

% of portfolio

0.06%

Previous 0.06%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$108.01 - $179.35 $16.5 Million - $27.4 Million	-152,538 Reduced 32.15%	321,946 $57.3 Million
Q4 2023 Feb 08, 2024	BUY	$96.0 - $128.29 $23.1 Million - $30.9 Million	240,863 Added 103.1%	474,484 $58.9 Million
Q3 2023 Nov 13, 2023	SELL	$108.51 - $130.22 $25.3 Million - $30.4 Million	-233,567 Reduced 49.99%	233,621 $27.1 Million
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $13 Million - $21.6 Million	-165,636 Reduced 26.17%	467,188 $54.8 Million
Q1 2023 May 10, 2023	SELL	$72.39 - $84.27 $3.62 Million - $4.22 Million	-50,056 Reduced 7.33%	632,824 $50.7 Million

Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $278,447 - $352,359	4,410 Added 0.65%	682,880 $54.1 Million
Q3 2022 Nov 10, 2022	SELL	$64.85 - $82.4 $1.58 Million - $2.01 Million	-24,433 Reduced 3.48%	678,470 $47.3 Million
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $2.69 Million - $4.04 Million	-54,956 Reduced 7.25%	702,903 $46.2 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $217,266 - $301,347	4,179 Added 0.55%	757,859 $50.4 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $727,487 - $1.61 Million	-18,274 Reduced 2.37%	753,680 $52.7 Million
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $292,764 - $403,993	5,629 Added 0.73%	771,954 $40.3 Million
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $812,480 - $1.07 Million	-13,075 Reduced 1.68%	766,325 $52.1 Million
Q1 2021 May 14, 2021	BUY	$59.42 - $85.46 $230,074 - $330,901	3,872 Added 0.5%	779,400 $60 Million
Q4 2020 Feb 12, 2021	BUY	$40.64 - $61.38 $51,775 - $78,198	1,274 Added 0.16%	775,528 $46.5 Million
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $3.46 Million - $4.45 Million	91,710 Added 13.44%	774,254 $33.3 Million
Q2 2020 Aug 12, 2020	BUY	$37.03 - $60.0 $3.78 Million - $6.13 Million	102,108 Added 17.59%	682,544 $28.3 Million
Q1 2020 May 13, 2020	BUY	$35.02 - $65.64 $10.5 Million - $19.7 Million	299,818 Added 106.84%	580,436 $25.1 Million
Q4 2019 Feb 12, 2020	BUY	$33.17 - $65.23 $7.06 Million - $13.9 Million	212,981 Added 314.89%	280,618 $15.5 Million
Q3 2019 Nov 12, 2019	SELL	$34.72 - $51.3 $54,684 - $80,797	-1,575 Reduced 2.28%	67,637 $2.35 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $1.88 Million - $2.85 Million	69,212 New	69,212 $2.79 Million

Others Institutions Holding KRYS

# of Institutions

262

Shares Held

21.5M

Call Options Held

462K

Put Options Held

723K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.56B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account